NCT03570658View on ClinicalTrials.gov

A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 24, 2018

Primary Completion Date

January 28, 2019

Study Completion Date

January 28, 2019

Conditions
Hepatitis B Virus
Interventions
DRUG

RO7049389

RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).

DRUG

Placebo

Placebo will be administered orally at a dose and frequency matched to RO7049389.

Trial Locations (1)

200040

Huashan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03570658 - A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter